A Phase 1/2 interventional study of BMS-986258 and Nivolumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Terminated at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BMS-986258
Biological: BMS-986258 · Drug: rHuPH20
Biological: BMS-986258 · Biological: Nivolumab
Biological: BMS-986258 · Biological: Nivolumab
Number of Participants With Adverse Events (AEs)
An Adverse Event (AE) is any new untoward medical occurrence or worsening of a preexisting medical condition in a study participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect.
Time frame: From first dose until 100 days after last dose of study therapy (up to approximately 78 weeks)
Number of Participants Who Died During the Study
The number of participants who died during the study.
Time frame: From first dose until death due to any cause (up to approximately 78 months)
Number of Participants With Dose Limiting Toxicities (DLTs)
Dose-limiting toxicity (DLT) refers to a side effect or adverse reaction caused by a drug that is severe enough to prevent an increase in dose or level of that drug. It is typically identified during clinical trials to determine the highest dose of a drug that can be given safely without causing unacceptable side effects. A participant was considered DLT evaluable if they received 1 dose of BMS-986258 in Part A or 1 dose of BMS-986258 and nivolumab 480mg in Part B and completed the DLT observation period. Participants who withdraw from the study during the 4-week DLT evaluation period for reasons other than a DLT may be replaced with a new participant at the same dose level.
Time frame: From first dose (Cycle 1 Day 1) until day 28 (Cycle 1 Day 28)
Objective Response Rate (ORR)
Objective response rate (ORR) is defined as the percent of treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose until disease progression or death, whichever occurred first (up to approximately 78 months)
Median Duration of Response (mDOR)
Median duration of response (mDOR) for a participant with a best overall response (BOR) of complete response (CR) or partial response (PR) is defined as the time between the date of first response and the date of the first objectively documented disease progression (DP) per RECIST v1.1 or death, whichever occurred first. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Disease Progression (DP): At least a 20% increase in the sum of the diameters of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions. Based on Kaplan-Meier estimates.
Time frame: From first dose until disease progression or death whichever occurred first (up to approximately 78 months)
Progression-Free Survival (PFS) Rate at 6, 9, and 12 Months
Progression free survival (PFS) for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurred first. Disease Progression (DP): At least a 20% increase in the sum of the diameters of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
Time frame: At 6, 9, and 12 months after first dose
Maximum Plasma Concentration (Cmax) of BMS-986258
Cmax (Maximum Concentration) is the highest level of a drug in the blood after it has been taken. It shows the peak level of the drug, which helps in understanding how much of the drug is absorbed and how strong its effects might be.
Time frame: Part A and B: On Cycle 1 Day 1 and Cycle 3 Day 1 (1 cycle = 8 weeks); Part A1: On Cycle 1 Day 1 and Cycle 1 Day 29 (1 cycle = 8 weeks)
Area Under the Curve From Time 0 to T (AUC(0-T)) of BMS-986258
AUC (0-T) is the total exposure to the drug over a specific period; from the time you take it until a specified time. It helps in understanding the overall amount of drug that has been in your body over that time period.
Time frame: Part A and B: On Cycle 1 Day 1 and Cycle 3 Day 1 (1 cycle = 8 weeks); Part A1: On Cycle 1 Day 1 and Cycle 1 Day 29 (1 cycle = 8 weeks)
Area Under the Curve Over the Dosing Interval AUC(TAU) of BMS-986258
AUC(TAU) (Area Under the Curve over the Dosing Interval) is the total exposure to the drug over one complete dosing interval (the time between doses). It helps in understanding how much of the drug is in your body over the entire period between doses, which is important for determining the right dosing schedule.
Time frame: Part A and B: 0 to 28 days post-dose on Cycle 1 Day 1 and Cycle 3 Day 1 (1 cycle = 8 weeks); Part A1: 0 to 28 days post-dose on Cycle 1 Day 1 and Cycle 1 Day 29 (1 cycle = 8 weeks)
Concentration at the End of the Dosing Interval (Ctau) of BMS-986258
Ctau (Concentration at the End of the Dosing Interval) is the level of the drug in the blood just before the next dose is due. It shows how much of the drug remains in your body before taking the next dose, which helps in ensuring that the drug levels stay effective without dropping too low.
Time frame: Part A and B: On Cycle 1 Day 29 and Cycle 3 Day 29 (1 cycle = 8 weeks); Part A1: On Cycle 1 Day 29 and Cycle 2 Day 1 predose (1 cycle = 8 weeks)
Time to Reach Maximum Concentration (Tmax) of BMS-986258
Tmax (Time to Reach Maximum Concentration) is the time it takes for the drug to reach its highest level in the blood after taking it. It helps in understanding how quickly the drug starts to work and reaches its peak effect.
Time frame: Part A and B: On Cycle 1 Day 1 and Cycle 3 Day 1 (1 cycle = 8 weeks); Part A1: On Cycle 1 Day 1 and Cycle 1 Day 29 (1 cycle = 8 weeks)
Number of Participants With Anti-Drug Antibodies to BMS-986258 or Nivolumab
Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment
Time frame: From first dose until 100 days after last dose of study therapy (up to approximately 78 weeks)
| Milestone | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 4 | 4 | 9 | 3 | 5 | 8 | 4 | 11 | 4 | 15 | 15 |
| Transitioned from part a1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 8 | 6 |
| Not completed | 3 | 3 | 4 | 4 | 4 | 9 | 3 | 5 | 4 | 4 | 10 | 4 | 7 | 9 |
| Withdrew: Disease progression | 3 | 3 | 3 | 4 | 4 | 6 | 3 | 4 | 2 | 4 | 9 | 3 | 7 | 7 |
| Withdrew: Study drug toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Withdrew: Participant requested to discontinue study treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Not reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An Adverse Event (AE) is any new untoward medical occurrence or worsening of a preexisting medical condition in a study participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event) * Requires inpatient hospitalization or causes prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect.
| Participants | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Events (AEs) | 3 | 3 | 4 | 4 | 4 | 8 | 2 | 5 | 8 | 4 | 11 | 6 | 17 | 13 |
| Serious Adverse Events (SAEs) | 1 | 2 | 3 | 1 | 0 | 4 | 1 | 3 | 2 | 2 | 6 | 1 | 6 | 3 |
| Adverse Events (AEs) leading to discontinuation of study treatment | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
The number of participants who died during the study.
| Participants | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Died During the Study | 3 | 3 | 3 | 3 | 3 | 7 | 3 | 4 | 5 | 3 | 9 | 0 | 10 | 8 |
Dose-limiting toxicity (DLT) refers to a side effect or adverse reaction caused by a drug that is severe enough to prevent an increase in dose or level of that drug. It is typically identified during clinical trials to determine the highest dose of a drug that can be given safely without causing unacceptable side effects. A participant was considered DLT evaluable if they received 1 dose of BMS-986258 in Part A or 1 dose of BMS-986258 and nivolumab 480mg in Part B and completed the DLT observation period. Participants who withdraw from the study during the 4-week DLT evaluation period for reasons other than a DLT may be replaced with a new participant at the same dose level.
| Participants | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Objective response rate (ORR) is defined as the percent of treated participants whose best overall response (BOR) is either complete response (CR) or partial response (PR) per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Percent of Participants | Part A: All Doses | Part B: All Doses | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|
| Objective Response Rate (ORR) | 0 (0.00 to 8.22) | 5.4 (0.66 to 18.19) | 0 (0.00 to 21.80) |
Median duration of response (mDOR) for a participant with a best overall response (BOR) of complete response (CR) or partial response (PR) is defined as the time between the date of first response and the date of the first objectively documented disease progression (DP) per RECIST v1.1 or death, whichever occurred first. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Disease Progression (DP): At least a 20% increase in the sum of the diameters of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions. Based on Kaplan-Meier estimates.
| Months | Part A: All Doses | Part B: All Doses | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|
| Median Duration of Response (mDOR) | — | NA (NA to NA) | — |
Progression free survival (PFS) for a participant is defined as the time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurred first. Disease Progression (DP): At least a 20% increase in the sum of the diameters of target lesions, with an absolute increase of at least 5 mm, or the appearance of new lesions.
| Percent of Participants | Part A: All Doses | Part B: All Doses | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|
| 6-month | 21.4 (9.3 to 36.8) | 21.9 (8.4 to 39.3) | 8.7 (0.5 to 32.0) |
| 9-month | 17.1 (6.2 to 32.6) | 8.2 (0.8 to 27.7) | 8.7 (0.5 to 32.0) |
| 12-month | 17.1 (6.2 to 32.6) | 0.0 (NA to NA) | 0.0 (NA to NA) |
Cmax (Maximum Concentration) is the highest level of a drug in the blood after it has been taken. It shows the peak level of the drug, which helps in understanding how much of the drug is absorbed and how strong its effects might be.
| ug/mL | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.27 ± 53.8 | 5.34 ± 36.2 | 31.5 ± 10.9 | 47.2 ± 120 | 121 ± 30.7 | 239 ± 35.6 | 423 ± 12.9 | 412 ± 26.7 | 890 ± 29.2 | 154 ± 43.4 | 244 ± 24.8 | 449 ± 31.5 | 579 ± 19.4 | 121 ± 44.1 |
| Cycle 3 Day 1 | — | 9.26 ± NA | — | 50 ± NA | — | 356 ± NA | — | — | 605 ± NA | 111 ± NA | 161 ± NA | 422 ± NA | 684 ± 18.1 | — |
| Cycle 1 Day 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | 479 ± 21.2 |
AUC (0-T) is the total exposure to the drug over a specific period; from the time you take it until a specified time. It helps in understanding the overall amount of drug that has been in your body over that time period.
| h*ug/mL | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 53.7 ± 50.8 | 457 ± 56 | 4690 ± 43.3 | 8180 ± 101 | 26100 ± 46.7 | 46000 ± 83.9 | 97000 ± 23.3 | 75300 ± 44.5 | 179000 ± 24.3 | 29000 ± 51.4 | 44300 ± 34.9 | 84100 ± 83.2 | 118000 ± 25.4 | 48500 ± 51.1 |
| Cycle 3 Day 1 | — | 1400 ± NA | — | 13400 ± NA | — | 102000 ± NA | — | — | 135000 ± NA | 29800 ± NA | 38200 ± NA | 89000 ± NA | 171000 ± 27 | — |
| Cycle 1 Day 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | 138000 ± 21 |
AUC(TAU) (Area Under the Curve over the Dosing Interval) is the total exposure to the drug over one complete dosing interval (the time between doses). It helps in understanding how much of the drug is in your body over the entire period between doses, which is important for determining the right dosing schedule.
| h*ug/mL | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | 587 ± 41.9 | 4870 ± 43.7 | 8400 ± 105 | 26900 ± 47.4 | 56400 ± 45 | 100000 ± 18 | 85800 ± 21.9 | 187000 ± 29.5 | 29000 ± 51.4 | 47300 ± 29.4 | 89600 ± 67.9 | 120000 ± 22.5 | 46200 ± 53.9 |
| Cycle 3 Day 1 | — | 1440 ± NA | — | 13400 ± NA | — | 102000 ± NA | — | — | 135000 ± NA | 18600 ± NA | 38200 ± NA | 89000 ± NA | 172000 ± 26.1 | — |
| Cycle 1 Day 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | 134000 ± 17.3 |
Ctau (Concentration at the End of the Dosing Interval) is the level of the drug in the blood just before the next dose is due. It shows how much of the drug remains in your body before taking the next dose, which helps in ensuring that the drug levels stay effective without dropping too low.
| ug/mL | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 29 predose | — | 0.0245 ± 52.3 | 1.58 ± 116 | 2.59 ± 369 | 15.5 ± 68.6 | 37.2 ± 62.9 | 55.7 ± 55.2 | 36.9 ± 68.5 | 109 ± 44.6 | 15.6 ± 82.3 | 23.5 ± 70.3 | 39.8 ± 229 | 68.4 ± 47.1 | 37.7 ± 80.2 |
| Cycle 3 Day 29 predose | — | 0.0711 ± NA | — | 8.32 ± NA | — | 80.3 ± NA | — | — | 71.3 ± NA | 7.77 ± NA | 25 ± NA | 37.1 ± NA | 121 ± 36.6 | — |
| Cycle 2 Day 1 predose | — | — | — | — | — | — | — | — | — | — | — | — | — | 114 ± 13 |
Tmax (Time to Reach Maximum Concentration) is the time it takes for the drug to reach its highest level in the blood after taking it. It helps in understanding how quickly the drug starts to work and reaches its peak effect.
| Hours | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.808 (0.033 to 4) | 1.23 (0.117 to 4) | 1.4 (0.45 to 4) | 2.11 (0.45 to 24.5) | 3.92 (0.617 to 24) | 0.998 (0.467 to 4.13) | 1.09 (0.467 to 4.38) | 1.47 (1.47 to 1.48) | 3.11 (2 to 4.05) | 0.812 (0.467 to 4) | 4.18 (4 to 4.58) | 1.02 (0.983 to 1.07) | 2.29 (1.47 to 5.52) | 123 (72.2 to 168) |
| Cycle 3 Day 1 | — | 4 (4 to 4) | — | 0.7 (0.7 to 0.7) | — | 4.27 (4 to 4.55) | — | — | 2 (2 to 2) | 0.499 (0.467 to 0.533) | 0.467 (0.467 to 0.467) | 2.02 (1.02 to 4) | 2.74 (1.47 to 5.48) | — |
| Cycle 1 Day 29 | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.26 (0.967 to 2.33) |
Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment
| Participants | Part A: All Doses | Part B: All Doses | Part A1: BMS-986258 1200 mg + ENHANZE |
|---|---|---|---|
| Baseline ADA positive: BMS-986258 | 0 | 0 | 0 |
| ADA positive: BMS-986258 | 2 | 0 | 0 |
| Baseline ADA positive: nivolumab | — | 1 | 0 |
| ADA positive: nivolumab | — | 2 | 0 |
Collected over All-cause mortality (ACM) was assessed from first dose until death due to any cause (up to approximately 78 months). Serious-adverse events (AEs) and Other adverse events (AEs) were assessed from first dose until 100 days after last dose of study therapy (up to approximately 78 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: BMS-986258 8 mg | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part A: BMS-986258 24 mg | 3/3 (100%) | 2/3 (66.7%) | 2/3 (66.7%) |
| Part A: BMS-986258 72 mg | 3/4 (75%) | 3/4 (75%) | 4/4 (100%) |
| Part A: BMS-986258 200 mg | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| Part A: BMS-986258 480 mg | 3/4 (75%) | 0/4 (0%) | 4/4 (100%) |
| Part A: BMS-986258 800 mg | 7/9 (77.8%) | 4/9 (44.4%) | 8/9 (88.9%) |
| Part A: BMS-986258 1200 mg | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part A: BMS-986258 1600 mg | 4/5 (80%) | 3/5 (60%) | 5/5 (100%) |
| Part A: BMS-986258 2400 mg | 5/8 (62.5%) | 2/8 (25%) | 8/8 (100%) |
| Part B: BMS-986258 480 mg + NIVO 480 mg | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Part B: BMS-986258 800 mg + NIVO 480 mg | 9/11 (81.8%) | 6/11 (54.5%) | 9/11 (81.8%) |
| Part B: BMS-986258 1200 mg + NIVO 480 mg | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Part B: BMS-986258 1600 mg + NIVO 480 mg | 10/15 (66.7%) | 6/15 (40%) | 15/15 (100%) |
| Part A1: BMS-986258 1200 mg + ENHANZE | 7/11 (63.6%) | 3/11 (27.3%) | 9/11 (81.8%) |
| Part A1 Crossover to Part B: 1200 mg BMS + 480 mg Nivo | 1/2 (50%) | 0/2 (0%) | 2/2 (100%) |
| Part A1 Crossover to Part B: 1600 mg BMS + 480 mg Nivo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Part A1 Crossover to Part B: 1200 mg BMS + 480 mg Nivo | Part A1 Crossover to Part B: 1600 mg BMS + 480 mg Nivo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/3 | 2/4 | 1/4 | 0/4 | 3/9 | 0/3 | 1/5 | 1/8 | 1/4 | 1/11 | 0/4 | 2/15 | 2/11 | 0/2 | 0/2 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 1/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| General physical health deteriorationGeneral disorders | 1/3 | 0/3 | 1/4 | 0/4 | 0/4 | 1/9 | 1/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 1/4 | 0/4 | 0/4 | 0/9 | 0/3 | 1/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| SepsisInfections and infestations | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 1/4 | 1/15 | 0/11 | 0/2 | 0/2 |
| DehydrationMetabolism and nutrition disorders | 0/3 | 0/3 | 1/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| Confusional statePsychiatric disorders | 0/3 | 0/3 | 0/4 | 1/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| HaematuriaRenal and urinary disorders | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 1/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 1/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 0/2 | 0/2 |
| Event | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Part A1 Crossover to Part B: 1200 mg BMS + 480 mg Nivo | Part A1 Crossover to Part B: 1600 mg BMS + 480 mg Nivo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 1/4 | 1/4 | 0/4 | 0/9 | 0/3 | 0/5 | 2/8 | 0/4 | 0/11 | 1/4 | 1/15 | 0/11 | 0/2 | 2/2 |
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 2/4 | 1/4 | 1/4 | 0/9 | 1/3 | 2/5 | 2/8 | 0/4 | 4/11 | 1/4 | 2/15 | 1/11 | 2/2 | 2/2 |
| FatigueGeneral disorders | 1/3 | 1/3 | 3/4 | 1/4 | 2/4 | 4/9 | 1/3 | 1/5 | 3/8 | 1/4 | 6/11 | 0/4 | 4/15 | 3/11 | 0/2 | 0/2 |
| Abdominal painGastrointestinal disorders | 0/3 | 2/3 | 2/4 | 1/4 | 1/4 | 0/9 | 0/3 | 0/5 | 2/8 | 0/4 | 0/11 | 1/4 | 0/15 | 1/11 | 0/2 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 2/3 | 1/4 | 0/4 | 1/4 | 0/9 | 0/3 | 1/5 | 1/8 | 2/4 | 3/11 | 1/4 | 2/15 | 1/11 | 0/2 | 1/2 |
| VomitingGastrointestinal disorders | 0/3 | 1/3 | 0/4 | 1/4 | 1/4 | 0/9 | 2/3 | 1/5 | 3/8 | 0/4 | 1/11 | 0/4 | 0/15 | 1/11 | 1/2 | 0/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 1/9 | 2/3 | 2/5 | 0/8 | 0/4 | 1/11 | 0/4 | 2/15 | 1/11 | 0/2 | 0/2 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/3 | 2/4 | 2/4 | 1/4 | 2/9 | 1/3 | 2/5 | 5/8 | 0/4 | 3/11 | 1/4 | 2/15 | 1/11 | 1/2 | 1/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 0/4 | 0/11 | 0/4 | 0/15 | 0/11 | 1/2 | 0/2 |
| HypothyroidismEndocrine disorders | 0/3 | 0/3 | 0/4 | 0/4 | 0/4 | 0/9 | 0/3 | 0/5 | 0/8 | 1/4 | 0/11 | 0/4 | 0/15 | 0/11 | 1/2 | 0/2 |
| Age, Continuous(Years) | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.7 ± 16.17 | 45.7 ± 6.03 | 61.5 ± 3.11 | 67.0 ± 4.24 | 60 ± 12.44 | 61.1 ± 7.10 | 65.3 ± 8.33 | 54.8 ± 8.07 | 58.4 ± 5.85 | 64.5 ± 5.07 | 62.5 ± 7.75 | 57.3 ± 16.2 | 58.5 ± 15.0 | 57.8 ± 12.27 | 59.6 ± 10.62 |
| Sex: Female, Male(Participants) | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 4 | 3 | 1 | 4 | 3 | 1 | 2 | 2 | 3 | 2 | 5 | 4 | 35 |
| Male | 2 | 3 | 0 | 1 | 3 | 5 | 0 | 4 | 6 | 2 | 8 | 2 | 10 | 11 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Not Hispanic or Latino | 2 | 3 | 4 | 4 | 3 | 8 | 3 | 5 | 8 | 3 | 10 | 4 | 11 | 14 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 6 |
| Race (NIH/OMB)(Participants) | Part A: BMS-986258 8 mg | Part A: BMS-986258 24 mg | Part A: BMS-986258 72 mg | Part A: BMS-986258 200 mg | Part A: BMS-986258 480 mg | Part A: BMS-986258 800 mg | Part A: BMS-986258 1200 mg | Part A: BMS-986258 1600 mg | Part A: BMS-986258 2400 mg | Part B: BMS-986258 480 mg + NIVO 480 mg | Part B: BMS-986258 800 mg + NIVO 480 mg | Part B: BMS-986258 1200 mg + NIVO 480 mg | Part B: BMS-986258 1600 mg + NIVO 480 mg | Part A1: BMS-986258 1200 mg + ENHANZE | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 3 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 9 |
| White | 2 | 0 | 2 | 2 | 2 | 7 | 2 | 2 | 5 | 3 | 8 | 2 | 8 | 10 | 55 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Aug 2024, 77 months.
Results were first posted in Sep 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.